Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (Leukemia, (2020), 34, 7, (1751-1759), 10.1038/s41375-020-0725-0)
- Resource Type
- Authors
- Ossenkoppele, G. J.; Breems, D. A.; Stuessi, G.; van Norden, Y.; Bargetzi, M.; Biemond, B. J.; A von dem Borne, P.; Chalandon, Y.; Cloos, J.; Deeren, D.; Fehr, M.; Gjertsen, B. T.; Graux, C.; Huls, G.; Janssen, J. J.J.W.; Jaspers, A.; Jongen-Lavrencic, M.; de Jongh, E.; Klein, S. K.; Van der Klift, M.; Van Marwijk Kooy, M.; Maertens, J.; Michaux, L.; van der Poel, M. W.M.; Van Rhenen, A.; Tick, L.; Valk, P.; Vekemans, M. C.; van der Velden, W. J.F.M.; de Weerdt, O.; Pabst, T.; Manz, M.; Löwenberg, B.; Havelange; Moors, I.; van Obberg, F.; Maertens, J. A.; Hodossy, B.; Vansteenweghen, S.; Lammertijn, L.; Sonet, A.; Triffet, A.; Passweg, J.; Heim, D.; Giovanni, San; Stuessi, Georg; Betticher, D.; Spertini, O.; Gregor, M.; Hess, U.; Manz, M. G.; van de Loosdrecht, A.; Janssen, J. J.W.M.; van Esser, J. W.J.; Brouwer, R. E.; Van Lammeren-Venema, D.; Levin, M. D.; Tick, L. W.; Legdeur, M. C.J.C.; Vellenga, E.; Hoogendoorn, M.; Veelken, J. H.; von dem Borne, P. A.; Schouten, H. C.; Cornelissen, J.; Wouters, B.; Raaijmakers, H. G.M.; Kuball, J.
- Source
- Leukemia, 34(10). Nature Publishing Group
Ossenkoppele, G J, Breems, D A, Stuessi, G, van Norden, Y, Bargetzi, M, Biemond, B J, A von dem Borne, P, Chalandon, Y, Cloos, J, Deeren, D, Fehr, M, Gjertsen, B T, Graux, C, Huls, G, Janssen, J J J W, Jaspers, A, Jongen-Lavrencic, M, de Jongh, E, Klein, S K, Van der Klift, M, Van Marwijk Kooy, M, Maertens, J, Michaux, L, van der Poel, M W M, Van Rhenen, A, Tick, L, Valk, P, Vekemans, M C, van der Velden, W J F M, de Weerdt, O, Pabst, T, Manz, M, Löwenberg, B, Breems, D A, Havelange, Vekemans, M C, Moors, I, van Obberg, F, Maertens, J A, Hodossy, B, Vansteenweghen, S, Lammertijn, L, Deeren, D, Graux, C, Sonet, A, Triffet, A, Gjertsen, B T, Bargetzi, M, Passweg, J, Heim, D, Giovanni, S, Stuessi, G, Pabst, T, Betticher, D, Chalandon, Y, Spertini, O, Gregor, M, Hess, U, Fehr, M, Manz, M G, Klein, S K, Biemond, B J, Ossenkoppele, G J, van de Loosdrecht, A, Janssen, J J W M, van Esser, J W J, Van der Klift, M, Brouwer, R E, Van Lammeren-Venema, D, Levin, M D, Tick, L W, Legdeur, M C J C, Huls, G, Vellenga, E, Hoogendoorn, M, Veelken, J H, von dem Borne, P A, Schouten, H C, de Weerdt, O, van der Velden, W J F M, Cornelissen, J, Jongen-Lavrencic, M, Wouters, B, Raaijmakers, H G M, Löwenberg, B, Kuball, J, Van Rhenen, A, Van Marwijk Kooy, M & for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) 2020, ' Correction : Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (Leukemia, (2020), 34, 7, (1751-1759), 10.1038/s41375-020-0725-0) ', Leukemia, vol. 34, no. 10 . https://doi.org/10.1038/s41375-020-0994-7
- Subject
- Language
- English
- ISSN
- 0887-6924
An amendment to this paper has been published and can be accessed via a link at the top of the paper.